Article

Collaboration: Pfizer, Eyetech in deal for AMD, DME therapy

New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).

Related Videos
Image credit: Ophthalmology Times; Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
© 2025 MJH Life Sciences

All rights reserved.